Anderson A D G, McNaught C E, Jain P K, MacFie J
Combined Gastroenterology Research Group, Scarborough Hospital, Woodlands Drive, Scarborough YO12 6QL, UK.
Gut. 2004 Feb;53(2):241-5. doi: 10.1136/gut.2003.024620.
It is possible to manipulate the composition of the gastrointestinal microflora by administration of pre- and probiotics. This may help to preserve gut barrier function and reduce the incidence of septic morbidity.
To assess the effects of a combination of pre- and probiotics (synbiotic) on bacterial translocation, gastric colonisation, systemic inflammation, and septic morbidity in elective surgical patients.
Patients were enrolled two weeks prior to elective abdominal surgery. Seventy two patients were randomised to the synbiotic group and 65 to the placebo group. Patients were well matched regarding age and sex distribution, diagnoses, and POSSUM scores.
Patients in the synbiotic group received a two week preoperative course of Lactobacillus acidophilus La5, Bifidobacterium lactis Bb-12, Streptococcus thermophilus, and Lactobacillus bulgaricus, together with the prebiotic oligofructose. Patients in the placebo group received placebo capsules and sucrose powder. At surgery, a nasogastric aspirate, mesenteric lymph node, and scrapings of the terminal ileum were harvested for microbiological analysis. Serum was collected preoperatively and on postoperative days 1 and 7 for measurement of C reactive protein, interleukin 6, and antiendotoxin antibodies. Septic morbidity and mortality were recorded.
There were no significant differences between the synbiotic and control groups in bacterial translocation (12.1% v 10.7%; p = 0.808, chi(2)), gastric colonisation (41% v 44%; p = 0.719), systemic inflammation, or septic complications (32% v 31%; p = 0.882).
In this study, synbiotics had no measurable effect on gut barrier function in elective surgical patients. Further studies investigating the place of pre- and probiotics in clinical practice are required.
通过给予益生元和益生菌可以调节胃肠道微生物群的组成。这可能有助于维持肠道屏障功能并降低脓毒症发病率。
评估益生元和益生菌联合制剂(合生元)对择期手术患者细菌移位、胃定植、全身炎症反应和脓毒症发病率的影响。
在择期腹部手术前两周纳入患者。72例患者被随机分为合生元组,65例被分为安慰剂组。两组患者在年龄、性别分布、诊断及POSSUM评分方面匹配良好。
合生元组患者在术前接受为期两周的嗜酸乳杆菌La5、双歧杆菌Bb-12、嗜热链球菌和保加利亚乳杆菌治疗,同时给予益生元低聚果糖。安慰剂组患者接受安慰剂胶囊和蔗糖粉。手术时,采集鼻胃吸出物、肠系膜淋巴结及回肠末端刮片进行微生物学分析。术前及术后第1天和第7天采集血清,检测C反应蛋白、白细胞介素6及抗内毒素抗体。记录脓毒症发病率和死亡率。
合生元组与对照组在细菌移位(12.1%对10.7%;p = 0.808,卡方检验)、胃定植(41%对44%;p = 0.719)、全身炎症反应或脓毒症并发症(32%对31%;p = 0.882)方面无显著差异。
在本研究中,合生元对择期手术患者的肠道屏障功能无明显影响。需要进一步研究以明确益生元和益生菌在临床实践中的地位。